Hepatitis C Virus and Risk of Lymphoma and Other Lymphoid Neoplasms: A Meta-analysis of Epidemiologic Studies

Maso, Luigino Dal; Franceschi, Silvia

doi:10.1158/1055-9965.epi-06-0308

Cited by 265 publications

(202 citation statements)

References 36 publications

(78 reference statements)

Supporting

Mentioning

172

Contrasting

Unclassified

Order By: Relevance

“…Our results are consistent with the results of the resent meta-analysis by Dal Maso and Franceschi. 7 We found unadjusted ORs of 3.4, 3.6 and 1.8 for all NHL, B-cell and T-cell lymphomas, whereas the meta-analysis calculated ORs of 2.5 for all NHL, 2.7 for the major B-cell subtypes (diffuse large cell and follicular) and 1.5 for T-cell lymphomas.…”

Section: Discussionmentioning

confidence: 53%

“…6 The epidemiologic evidence concerning this potential association was recently reviewed. 7 Overall, there was a 2-fold risk of NHL associated with HCV, but there was significant heterogeneity found between studies based on study design and HCV prevalence. Higher risks were found with case-control studies particularly those using hospital controls and in studies in high HCV prevalence areas.…”

mentioning

confidence: 97%

See 1 more Smart Citation

Hepatitis C virus and risk of non‐Hodgkin lymphoma in British Columbia, Canada

Spinelli

Lai

Krajden

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

We investigated Hepatitis C virus (HCV) seropositivity and the risk of non-Hodgkin lymphoma (NHL) in a population-based case-control study in British Columbia, Canada. Cases were aged 20-79, diagnosed between March 2000 and February 2004, and resident in greater Vancouver or Victoria. Cases with HIV or a prior transplant were excluded. Controls were chosen from the Client Registry of the British Columbia (BC) Ministry of Health, and were age/sex/region frequency matched to cases. Antibodies for HCV were measured in 795 cases and 697 control subjects. HCV seropositivity was 2.4% in cases and 0.7% in controls [odds ratio (OR) 5 2.6, 95% confidence interval (CI) 5 0.9-7.4]. A significantly elevated risk was observed for B-cell lymphoma (OR 5 2.9, 95%CI 5 1.0-8.6). The highest risks were associated with diffuse large B-cell lymphoma (OR 5 7.3, 95%CI 5 2.1-25.0) and marginal zone lymphoma (OR 5 6.1, 95%CI 5 1.1-33.9). Our results provide further evidence that HCV infection contributes to NHL risk. ' 2007 Wiley-Liss, Inc.Key words: non-Hodgkin lymphoma; virus; hepatitis; hepatitis C; epidemiology; etiology The incidence of non-Hodgkin lymphoma (NHL) has been rising steadily for the past 30 years, but has leveled off in recent years. 1,2 Hepatitis C virus (HCV) infection is well-known to be the primary risk factor for type II mixed cryoglobulinemia (MC). 3,4 MC is a nonmalignant lymphoproliferative condition, which may evolve into B-cell NHL in 5-8% of cases. 5 This possible association between HCV infection and NHL was first suggested in 1993. 6 The epidemiologic evidence concerning this potential association was recently reviewed. 7 Overall, there was a 2-fold risk of NHL associated with HCV, but there was significant heterogeneity found between studies based on study design and HCV prevalence. Higher risks were found with case-control studies particularly those using hospital controls and in studies in high HCV prevalence areas.HCV was first identified in 1989, and was known as ''NonA, NonB Hepatitis'' to describe inflammatory liver disease not attributable to infection with Hepatitis A or Hepatitis B. 8 The World Health Organization estimates there are 170 million people, around 3% of the world's population, infected with hepatitis C, with 3-4 million new infections per year. 9 In Canada, it is estimated that there are 250,000 people (0.8%) infected with hepatitis C and that as few as 30% of those who have hepatitis C know they are infected. 10 The prevalence of HCV infection in British Columbia (BC) is estimated to be 1.5%, nearly twice the national rate, likely due to a high rate of injection drug use (IDU). 11,12 To further investigate the association between HCV infection and NHL in a low prevalence area, we examined data from a population-based case-control study in BC, Canada. Material and methods Study populationThe methodology has been described previously. 13 Between March 2000 and February 2004, NHL cases from the Greater Vancouver Regional District (GVRD) and the Capital Regional District (CRD), which i...

show abstract

Section: Discussionmentioning

confidence: 53%

mentioning

confidence: 97%

Hepatitis C virus and risk of non‐Hodgkin lymphoma in British Columbia, Canada

Spinelli

Lai

Krajden

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…These data are consistent with those reported by a previous study 19 but differ from those of another report. 5 We noted a spectrum of clinicopathological disorders, varying from patients with distinct clinical or histological evidence of lymphoma involving lymph node, spleen and/or extranodal tissues to cases in which monoclonal B-cell lymphocytosis was detected as the presence of a monoclonal B-cell population in peripheral blood, bone marrow and/or other tissues. There was a subset of cases with borderline, intermediate features.…”

Section: Discussionmentioning

confidence: 99%

“…For example, a significantly higher risk of non-Hodgkin lymphoma in HCVpositive patients has been noticed in several countries. [5][6][7] Although there have been several reports of the clinical characterization of the range of lymphoproliferative disorders associated with HCV infection, detailed morphological information and diagnostic features are still lacking, and as a consequence, malignancy is sometimes overdiagnosed. Additionally, little is known about the evolution of these disorders and their response to antiviral therapy.…”

mentioning

confidence: 99%

Hepatitis C virus-related lymphoproliferative disorders encompass a broader clinical and morphological spectrum than previously recognized: a clinicopathological study

et al. 2014

View full text Add to dashboard Cite

We describe a retrospective series of B-cell lymphoproliferative disorders associated with hepatitis C virus infection. In addition to splenic marginal zone lymphoma, follicular lymphoma and diffuse large B-cell lymphoma, all of which showed some specific features, we found two poorly described groups of cases. The first featured disseminated marginal zone lymphoma without splenic marginal zone lymphoma features, defying the current marginal zone lymphoma classification; the other consisted of monoclonal B lymphocytes in the peripheral blood, bone marrow or other tissues, with no clinical or histological evidence of lymphoma, and exhibiting a pattern that requires proper identification in order to avoid the misdiagnosis of the lymphoma. Diagnosis of hepatitis C virus infection-associated lymphoproliferative disorders requires the integration of clinical, pathological and molecular findings to establish an adequate diagnosis and decide the appropriate therapy to be applied.

show abstract

“…Previous studies have demonstrated an association between hepatitis C virus (HCV) infection and B-NHL [13] [14]. It has also been proposed that hepatitis B virus (HBV) may be an etiologic agent of Non-Hodgkin's Lymphoma (NHL) [15]- [17], but relatively few studies have investigated the association between HBV infection and B-NHL.…”

Section: Introductionmentioning

confidence: 99%

Hepatitis B Virus Infection in B-Cell Non-Hodgkin’s Lymphoma, and Effect of Entecavir in Prophylactic Antiviral Therapy

Chen¹,

Yi²,

Cen³

et al. 2016

Health

View full text Add to dashboard Cite

Background: specialized studies on hepatitis B virus (HBV) infection and B-NHL (B-cell Non-Hodgkin's Lymphoma) are limited, as well as prophylactic antiviral therapy for B-NHL patients with HBV infection who are receiving anticancer chemotherapy. This study aims to investigate the association between HBV infection and B-NHL, and to evaluate the effect of prophylactic antiviral therapy for HBV-infected B-NHL patients. Study design: A retrospective, case-control study was performed. The study group included 420 patients with B-NHL who were consecutively diagnosed from May 2003 to October 2013 (age range, 14 -71 years), and the control group included 1280 Chinese residents in Guangxi who participated in the Health Survey (age range, 18 -74 years). We compared the prevalence rate of HBV infection and clinic-pathologic characteristics between the two groups. The prevalence rate of HBV infection in our study was 34.7% (146/420), higher than the prevalence rate of 13.9% (178/1280) in the general population (P < 0.001). Among 146 B-NHL patients who received anticancer chemotherapy, 104 patients (71.2%) received prophylactic antiviral therapy. Conclusion: This study provides evidence that HBV may play an important role in development of B-NHL. Entecavir maybe the better antiviral drugs than Lamivudine, and antiviral therapy is maintained more than 6 months that maybe the optimal duration of prophylactic antiviral therapy. But further investigation should be conducted for determination of optimal duration and monitoring of antiviral therapy.

show abstract

Hepatitis C Virus and Risk of Lymphoma and Other Lymphoid Neoplasms: A Meta-analysis of Epidemiologic Studies

Cited by 265 publications

References 36 publications

Hepatitis C virus and risk of non‐Hodgkin lymphoma in British Columbia, Canada

Hepatitis C virus and risk of non‐Hodgkin lymphoma in British Columbia, Canada

Hepatitis C virus-related lymphoproliferative disorders encompass a broader clinical and morphological spectrum than previously recognized: a clinicopathological study

Hepatitis B Virus Infection in B-Cell Non-Hodgkin’s Lymphoma, and Effect of Entecavir in Prophylactic Antiviral Therapy

Contact Info

Product

Resources

About